Australasian Association of Nuclear Medicine Specialists

Australasian Association of Nuclear Medicine Specialists Position Statement: Actinium (Ac-225) PSMA August 2024

Background

Ac-225 PSMA is presently being used in Australia as a treatment for prostate cancer when other treatment options have been exhausted. Ac-225 is not registered by the Therapeutic Goods Administration (TGA) for use in Australia but can be administered under the Special Access Scheme (SAS) Category A for when a patient is seriously ill with a condition from which death is reasonably likely to occur within a matter of months, or from which premature death is reasonably likely to occur in the absence of early treatment.

There is presently insufficient clinical data, on both safety and the optimal dose for administration of Ac-225 to patients, to support general clinical use given the significant potential harm that this alpha emitting radionuclide could cause.

AANMS Current Position on the Use of Ac-225 PSMA in Australia

Until such time as the clinical data on both safety and the optimal dose for administration determine appropriate use the AANMS recommends that Ac-225 PSMA only be used either in a recognised clinical trial that has institutional ethics committee approval, or when recommended by a formal institutional multi-disciplinary team on a compassionate basis when all other recognised treatment options have been exhausted. Where it is considered for use outside of a clinical trial, the responsible doctor must ensure that the patient is fully aware of its investigational status, potential toxicity and the lack of significant safety and efficacy data. The responsible doctor must obtain fully informed consent.

Name of document and version:	Actinium (Ac-225) PSMA] v2
Approved by:	AANMS Board
Date of approval:	16 Aug 2024
Date for review:	2026

Disclaimer: The information provided in this position statement is of a general nature only and is notintended as a substitute for medical or legal advice. It is designed to support, not replace, the relationship that exists between a patient and his/her medical practitioner.

Australasian Association of Nuclear Medicine Specialists
PO Box 73 Balmain NSW 2041 Australia | ACN 158 642 267 | ABN 711 586 422 67
T +61 2 9818 4824 | E aanms@aanms.org.au | W www.aanms.org.au